In Depth

Investors optimistic about continued biotech and medtech IPO resurgence in 2025

ADCs breach barriers to become mainstream cancer treatment

WHO trial guidance goes beyond race and gender when tackling diversity

Mega M&A at JP Morgan Conference 2025 — is biopharma M&A poised for a rebound?

From Davids to Goliaths: the GLP- 1RA gold rush

Radiopharmaceutical trials face extra complexities due to nuclear red tape